
Gilead Sciences and Compugen have announced that they have entered an exclusive license agreement for Compugen’s potential first in class, …

AstraZeneca’s biologic R&D unit MedImmune is set to enter a partnership with Israeli drug firm Compugen to develop bi-specific and …
Bayer has entered into a new collaboration with Compugen to develop cancer vaccines aimed at helping the body fight off …
Aiforia deal to expand access to pathology AI
SMC accepts atogepant for acute migraine treatment in Scotland
New CCO Ogburn joins Cori Clinical
Claris reports visual acuity gains with experimental LSCD treatment
Amphista doses first patient in AML trial of protein degrader

